908 Devices (MASS) Projected to Post Quarterly Earnings on Tuesday

908 Devices (NASDAQ:MASS) is projected to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect 908 Devices to post earnings of ($0.06) per share and revenue of $16.1910 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:30 AM ET.

908 Devices Stock Down 0.9%

Shares of MASS opened at $6.90 on Friday. The firm has a market capitalization of $249.71 million, a PE ratio of -62.73 and a beta of 0.48. The stock’s fifty day simple moving average is $6.12 and its 200-day simple moving average is $6.65. 908 Devices has a 12-month low of $1.92 and a 12-month high of $9.34.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $12.00.

Insider Buying and Selling at 908 Devices

In other news, CFO Joseph H. Iv Griffith sold 23,175 shares of 908 Devices stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.18, for a total value of $143,221.50. Following the transaction, the chief financial officer owned 139,896 shares in the company, valued at approximately $864,557.28. This trade represents a 14.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 23.70% of the company’s stock.

Institutional Trading of 908 Devices

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its position in 908 Devices by 5.5% in the second quarter. Rhumbline Advisers now owns 36,416 shares of the company’s stock valued at $260,000 after acquiring an additional 1,894 shares during the last quarter. Graham Capital Management L.P. boosted its stake in shares of 908 Devices by 12.9% in the 4th quarter. Graham Capital Management L.P. now owns 20,787 shares of the company’s stock valued at $109,000 after purchasing an additional 2,374 shares in the last quarter. Cresset Asset Management LLC boosted its stake in shares of 908 Devices by 37.1% in the 3rd quarter. Cresset Asset Management LLC now owns 16,100 shares of the company’s stock valued at $141,000 after purchasing an additional 4,355 shares in the last quarter. Barclays PLC grew its holdings in shares of 908 Devices by 15.4% during the 4th quarter. Barclays PLC now owns 44,528 shares of the company’s stock valued at $234,000 after purchasing an additional 5,943 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in 908 Devices during the 2nd quarter worth approximately $48,000. 88.06% of the stock is currently owned by institutional investors.

About 908 Devices

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.